Tdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
Sağlık ve TıpOne-Off2ay
FutuurKullanılabilirliği kontrol etDoğrulanmış sonuçlanma verisiGüncel ima edilen olasılık
Hayır 93%
Hayır 93%Piyasa kalitesi
31 / 100
Düşük kalite24s Hacim
—
Likidite
₺13,8 B
Düşük likiditeİşlemciler
10
Yorumlar
0
Piyasa verileri
2 dakika önce güncellendi
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
How many clinical trials will have started in Prospera by Dec 31, 2026?
FutuurWill tabernanthalog (TBG) undergo Stage II clinical trials by EOY 2026?
Manifold MarketsWill a drug that didn't go through human clinical trials be approved by 2034?
Manifold MarketsWill it be possible to obtain FDA approval for a drug based on protein folding stimulations without human clinical trials by 2035?
Manifold MarketsWill human tooth regrowth clinical trials succeed?
Manifold MarketsHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
PolymarketKurallar
Researchers Jochen Buck and Lonny Levin of Weill Cornell Medicine have discovered a fast-acting and temporary male contraceptive called tdi-11861.
- This substance, a soluble adenylyl cyclase (sac) inhibitor, works by stopping sperm from swimming, rendering the subject temporarily infertile.
- According to initial studies in mice, it takes effect within half an hour, and fertility returns within a day.
- However, despite the encouraging results in mice, more animal tests and human trials are required before it can be confirmed as a breakthrough in male contraception.
- This prediction market aims to determine whether tdi-11861 will be approved for human clinical trials before or on December 31, 2026.
- The outcome will be determined based on an official announcement from the relevant regulatory bodies or agencies, such as the FDA, or news reports from major news outlets that Futuur deems credible.
